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Translational Relevance 
Our results highlight the dilemma of prostate cancer screening requiring careful 
assessment of the balance of benefits in terms of reduced prostate cancer mortality and 
harms in terms of overdetection of cases that would not have progressed to clinical 
disease even in the absence of screening. Our findings indicate that in a population-based 
screening program, 700-2000 men need to invited for screening to avert one prostate 
cancer death, depending on the screening algorithm and background risk in the 
population. The excess numbers of excess cases detected by screening are considerably 
larger, with one additional diagnosis per each 16-69 invited men. These result help 
providing clear and concrete guidance for the patient and deciding on the screening 
regimen (screening interval and PSA threshold) provided, as they show that approaches 
with the highest return in terms of prostate cancer mortality reduction also carry the most 
extensive overdetection. If the ratio of averted prostate cancer deaths and overdiagnosed 
cases (the pros and cons) is largely constant, more aggressive screening is justified 
mainly for high-risk groups that are likely to obtain the largest benefits (very likely men with 
little co-morbidity, those with family history) and those who do not emphasize the potential 
adverse effects of overdiagnosis (men who can cope with active surveillance as treatment 
strategy).   
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Running head: Absolute benefits and harms of prostate cancer screening 
ABSTRACT 
Purpose: The balance of benefits and harms in prostate cancer screening has not been 
sufficiently characterized. We related indicators of mortality reduction and overdetection by 
center within the European Randomised Study of Prostate Cancer Screening.  
Experimental Design: We analyzed the absolute mortality reduction expressed as 
number needed to invite (NNI=1/absolute risk reduction; indicating how many men had to 
be randomized to screening arm to avert a prostate cancer death) for screening and the 
absolute excess of prostate cancer detection as number needed for overdetection 
(NNO=1/absolute excess incidence; indicating the number of men invited per additional 
prostate cancer case), and compared their relationship across the seven ERSPC centers. 
Results: Both absolute mortality reduction (NNI) and absolute overdetection (NNO) varied 
widely between the centers: NNI 200-7000 and NNO 16-69. Extent of overdiagnosis and 
mortality reduction were closely associated (correlation coefficient r=0.76, weighted linear 
regression coefficient β=33, 95% 5-62, R2=0.72). For an averted prostate cancer death, 
12-36 excess cases had to be detected in various centers. 
Conclusions: The differences between the ERSPC centers likely reflect variations in 
prostate cancer incidence and mortality, as well as in screening protocol and performance. 
The strong interrelation between the benefits and harms suggests that efforts to maximize 
the mortality effect are bound to increase overdiagnosis, and might be improved by 
focusing on high-risk populations. The optimal balance between screening intensity and 
risk of overdiagnosis remains unclear. 
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Introduction 
Prostate cancer screening remains controversial despite evidence from the European 
Randomised Study of Screening for Prostate Cancer (ERSPC) showing a 20% reduction 
in prostate cancer mortality (1).  
The major adverse effect of prostate cancer screening is overdiagnosis, i.e. detection of 
cases that would not have been diagnosed during a man’s lifetime in the absence of 
screening. The extent of overdiagnosis has been estimated as 25-50% of the screen-
detected cases (4,5). Overdiagnosis is due to both substantial lead-time gained by 
screening and increased detection of slow-growing or even non-progressive disease. 
Overdiagnosis can rarely be recognized at individual level at the time of diagnosis based 
on pathological and clinical presentation alone, as it also depends on a man’s remaining 
life span. Therefore, the full extent of overdiagnosis can generally be shown only through 
comparison of screened and unscreened populations. However, modelling studies have 
suggested that if the long-term benefits of screening are predicted based on ERSPC, they 
would eventually outweigh the adverse effects in terms of quality-adjusted life-years (6).  
Absolute measures of effect (such as risk or rate difference) provide more concrete 
indication of intervention effect, as they reflect the probability of the benefit or adverse 
effect, i.e. the increase or decrease in frequency of occurrence (and hence usually also on 
the level of background risk). In contrast, relative measures (for instance rate ratio or risk 
ratio) do not capture this aspect and cannot be interpreted as probabilities of benefit and 
harm (unless combined with the underlying risk, as they express the effect as a multiple of 
the baseline risk). Due to the more tangible information provided by absolute effect 
measures, reporting guidelines for randomized trials recommend showing both types of 
results (7,8). Number needed to treat is the absolute measure used for treatment trials, 
and number needed to screen the equivalent metric for screening trials (9,10). To factor in 
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incomplete compliance in screening trials (particularly population-based effectiveness 
trials), number needed to invite has been developed as a further indicator of absolute 
screening effect (11). Absolute measures of effect depend, however, not only on screening 
procedures, but also on the duration of follow-up, background risk in study population (e.g. 
age distribution) and different studies are therefore not directly comparable. 
Within the ERSPC, there are differences in both study populations (e.g. underlying 
prostate cancer incidence and mortality), as well as screening procedures (despite 
common core protocol, e.g. in number of screening rounds). Here, we describe the 
differences in the absolute effect of screening, with number of men needed to invite to 
avoid one prostate cancer death (number needed to invite, NNI) as an indicator of the 
screening benefit and for harms, absolute risk of overdiagnosis expressed as number 
needed for overdiagnosis (NNO), calculated as the inverse of the excess risk (cumulative 
incidence) of prostate cancers in the screening versus control arm. The balance of the 
benefits and harms (NNI/NNO ratio) is expressed as the number of excess cases needed 
to detect for averting one prostate cancer death (number needed to detect, NND). The 
pooled ERSPC results based on the same data were published recently (1), and the 
present paper constitutes a secondary analysis. 
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Materials and Methods 
ERSPC is a randomized multi-center trial, with the primary aim to assess the effect of 
prostate-specific antigen (PSA) –based screening on prostate cancer mortality. The trial 
was initiated in the mid-1990’s (from 1991-1998) in seven centers (the Netherlands, 
Belgium, Sweden, Finland, Italy, Spain and Switzerland). France joined later, but was 
excluded from this analysis due to short follow-up. 
Men in the intervention arm were invited to PSA-based screening and those in the control 
arm received no intervention (usual care, Figure 1). Eligible subjects were identified from 
population registers and individually randomized based on random numbers (with 1:1 
allocation, except in Finland with a fixed size of the screening arm leading to an 
intervention/control ratio of approximately 1:1.5). Consent was obtained prior to 
randomization in most countries (volunteer-based efficacy trial), but randomization before 
consent was used in Sweden, Finland and Italy (population-based effectiveness trial). 
Recruitment was completed in all centers by the end of 2003. The screen interval was four 
years, except in Sweden a two-year interval was used. PSA determination with a cut-off of 
≥3.0 ng/ml was the principal screening test (an ancillary test was used at 3.0-3.9 ng/ml in 
Finland). Screen-positive men were referred to prostatic biopsies. Screening was 
discontinued after three screening rounds in most centers, but continued up to five times in 
the Netherlands and ten rounds in Sweden. Institutional review board approvals were 
obtained in each center. The ERSPC trial is registered in Current Controlled Trials as 
ISRCTN49127736. 
Data on deaths and emigrations were obtained from national or regional population 
registries. Prostate cancer cases detected outside screening (interval cases, cancers in 
non-participants and in the control arm) were identified through cancer registries. Prostate 
cancer deaths were ascertained in each center by causes of death committees that 
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evaluated all deaths in men diagnosed with prostate cancer and/or prostate as a cause of 
death in the death certificate, with blinding to the arm of the trial and following a uniform 
algorithm developed for the trial (12). In Finland, death certificates were used after the 
initial period, based on very high concordance between the committee assignments and 
the official causes of death (κ>0.9)(13). 
The present analysis is limited to the core age group, 55-69 years, to improve 
comparability between the centers. For the same reason, follow-up was truncated at 13 
years, even if data were available through 2010, potentially allowing longer follow-up in 
some centers. A mean length of follow-up of at least 13 years was available in all included 
centers, except only 10 years in Switzerland. The intention-to-screen principle was used in 
the analysis, with groups compared formed by random allocation (regardless of 
compliance).  
Number needed to invite (NNI) to avert one prostate cancer death was calculated as the 
inverse of the absolute risk difference in prostate cancer mortality between the arms 
(NNI=1/[Mc-Ms]) to indicate the mortality reduction by screening. As an indicator of 
overdiagnosis, number needed for overdetection (NNO) was calculated as the inverse of 
the risk difference in cumulative incidence of prostate cancer between the trial arms 
(NNO=1/[Is-Ic]), which represents the absolute risk of overdiagnosis (14). Finally, number 
needed to detect (NND) as a measure of the overall impact (benefits and harms) is shown 
as the ratio of the reduction in prostate cancer mortality to the excess prostate cancer 
incidence (NNI/NNO). In the calculation of number needed –indicators, the values are 
always rounded upward (to the next integer). For their interpretation, it is essential to 
appreciate that a smaller value indicates a larger effect. 
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Linear regression with weighting by number of prostate cancer deaths was used to assess 
the relationship between NNI and NNO between the centers, as well as in the analysis of 
the relation between the characteristics of the ERSPC centers (baseline risk, number of 
screens, proportion of positive screening tests and proportion of screen-positive men 
biopsied) and the impact measures (NNI, NNO and NND). The assumption of normal 
distribution was assessed using Shapiro-Wilks test. Poisson regression analysis was 
conducted with the numbers of cases as the outcome and number of men as the offset. 
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Results 
A summary of the screening performance by center is shown in Table 1. 
The size of the study population (within the core age group) ranged from in 2197 in Spain 
to 80,379 in Finland (Table 2). The proportion of men in the screening arm attending at 
least once was more than 90% in the volunteer-based centers and approximately 75% in 
the population-based centers. The proportion of positive tests was lowest (approximately 
11%) in Italy with a low prostate cancer incidence and in Finland, where an ancillary test 
(free/total PSA ratio with a cut-off 0.16) was used at PSA range 3.0-3.9. The proportion of 
positive tests was highest (>20%) in the Netherlands and Switzerland with various side 
studies involving additional tests.  
The highest cumulative incidence at 13 years in the screening arm was seen in Sweden 
and the Netherlands (12.5%), followed by Switzerland (11.6%) (Table 3). The cumulative 
incidence in the control arm was highest in Sweden (7.9%), followed by Finland and 
Belgium (7.5%). The excess incidence (difference in cumulative incidence between the 
arms) ranged from 1.5% in Italy to 6.3% in the Netherlands. The number needed for 
overdetection (NNO) ranged from 16-22 in the Netherlands, Switzerland and Sweden 
(indicating one excess case detected per approximately 20 screened men) to 47-69 in 
Finland, Belgium and Italy.  
When patients treated with active surveillance were excluded, the extent of overdetection 
was strongly reduced in Sweden (NNO increased from 22 to 41), Finland (from 51 to 137) 
and Switzerland (from 18 to 34), where active surveillance was commonly used, and also 
to some extent in Belgium (from 47 to 62), but the difference was not substantial in the 
other centers (in the Netherlands from 16 to 19, Italian and Spanish results almost 
unaltered due to infrequent use of active surveillance). 
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Prostate cancer mortality within the control arm was highest in Sweden (10 per 1000 men) 
followed by the Netherlands, Finland and Belgium, (approximately 5-7 per 1000) (Table 4). 
Also in the screening arm, prostate cancer mortality was highest in Sweden, Finland and 
the Netherlands (5-6 per 1000). A reduction in prostate cancer mortality was achieved in 
all centers except Switzerland. The absolute reduction was largest in Sweden (4 per 
1000), followed by the Netherlands and Belgium (1-2 per 1000). The mortality reduction 
relative to population size (NNI) ranged from 252 in Sweden to 1821 in Finland (not 
defined for Switzerland). 
The amount of mortality reduction per number of invited men (mean NNI) pooled across 
the centers was 855 (SD 576, excluding Switzerland) and the excess incidence relative to 
population size (mean NNO) was 36 (SD 20, including Switzerland). The variability 
between centers was slightly larger in mortality impact than excess detection (ratio of 
smallest to largest value 7 for NNI versus 4 NNO, SD 67% of the mean for NNI vs. 55% for 
NNO). When the probability of benefit (absolute reduction in prostate cancer mortality, 
NNI) was related to the probability of harm (excess incidence, NNO), Sweden and the 
Netherlands showed both the largest absolute mortality reduction and the highest absolute 
excess incidence (Figure 2). The other centers (Finland, Italy, Belgium and Spain) showed 
both lower mortality reduction (higher NNI) and less excess incidence (larger NNO). In 
Switzerland, however, a high excess incidence was not balanced by mortality reduction. 
The proportion of screen-positive results was significantly associated with both mortality 
reduction (NNI) and excess detection (NNO) (p=0.001 and r2>0.8 for both), but other 
center characteristics such as median age, number of screening rounds and baseline risk 
(prostate cancer incidence or mortality in the control arm) were not. 
The correlation coefficient for absolute mortality impact and absolute excess incidence 
(NNI and NNO) was 0.76 (excluding Switzerland) and linear regression coefficient (with 
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weighting of centers by number of prostate cancer deaths) was 33 (95% CI 5-62, p=0.03 
with R2=0.65), larger mortality reduction associated with larger overdetection, indicating 
intensive screening resulting in both large benefits and adverse effects. Adjustment for age 
in linear regression analysis did not weaken the association between mortality reduction 
and excess incidence (NNI and NNO). If Finland was excluded, the association was 
stronger (r=0.95, linear regression r2=0.84, p=0.02), while exclusion of the other major 
centers (Sweden or the Netherlands) did not substantially affect the result.  
A confirmatory Poisson regression analysis also showed a significant association between 
excess incidence of prostate cancer and reduction in prostate cancer mortality by center 
(p<0.001). 
The ratio of mortality reduction to excess incidence (mean NND, calculated as NNI/NNO) 
for the six centers was 22, with a range 12-36. It was smallest for Sweden (NND=12), 
indicating that the number of excess cases per averted prostate cancer death was less 
than in other centers, and largest for Finland (NND=36), with both smaller mortality 
reduction and excess incidence. Baseline risk (prostate cancer mortality in the control arm) 
showed little association with the excess incidence (NND), nor did number of screening 
rounds attended, proportion of positive screening tests, or proportion of screening-positive 
men biopsied (for all p>0.2, r2<0.2 in linear regression). 
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Discussion 
Our analysis of absolute measures of screening benefits (prostate cancer mortality 
reduction, NNI) and harms (excess prostate cancer incidence, NNO) shows that on 
average 12-36 excess prostate cancer have to be detected in order to avert one death 
from the disease. In comparison between the ERSPC centers, a direct correlation was 
observed between screening benefit and harm. This suggests that with the current 
screening regimens, any efforts to increase the effectiveness of screening are likely 
accompanied by unavoidable increase in the harmful effects. This was further supported 
by the association of the proportion of positive screening tests with both mortality reduction 
(NNI) and excess incidence (NNO). This could be attributable to the largely overlapping 
PSA distribution among fatal and overdiagnosed prostate cancer cases, i.e. PSA does not 
allow a sharp distinction of lethal and indolent prostate cancer in the early preclinical 
phase of the disease. This is further accentuated by the long lead-time (detection several 
years earlier – and at a younger age – compared with clinical diagnosis) and length bias 
(detection of slowly growing cancers with a long detectable pre-clinical phase by 
screening). 
Our results can be interpreted as suggesting a substantial overlap between cases that 
contribute to mortality reduction achievable by screening and those that would remain 
undetected in the absence of screening. This notion is supported by the fact that prediction 
of disease outcome in patients with low-risk features is highly uncertain and therefore 
distinguishing patients that would substantially benefit from treatment is challenging. This 
means that screen-detected cases include both tumors with indolent and progressive 
behavior, but we are currently unable to clearly discern the two. It is also consistent with 
trials showing only modest benefit from prostatectomy compared with expectant 
management in low-risk prostate cancer (15,16) and very high cause-specific survival in 
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patients treated with active surveillance (17), both indicating small advantage attainable by 
active treatment in men with a low-risk prostate cancer.  
The wide variation between the ERSPC centers in the outcomes appears to reflect mainly 
differences in screening protocols, as risks and benefits were not clearly associated with 
the underlying risks between the populations. Yield of screening depends on the cut-off 
value for the screening test, number of screening rounds and participation. These features 
are very likely to account for the differences in excess incidence, and hence the extent of 
overdetection.  
Of the various features, proportion of positive tests (reflecting PSA threshold and 
additional tests) was most closely associated with the absolute benefit and harm (NNI and 
NNO). There was less variation between the centers in the ratio of benefits and harms 
(NND=NNI/NNO) than in the mortality effect (three-fold versus seven-fold). This also 
supports the interpretation that increased mortality reduction is linked to a higher rate of 
overdiagnosis. Sweden showed the most favorable overall impact (in terms of balance of 
mortality reduction to excess incidence, NND) and Finland the smallest, despite the fact 
that the two centers share similar population-based approaches, with comparable 
participation and the highest prostate cancer mortality (both nationally and in the control 
arm). Possible explanations include differences in screening intensity or contamination. 
The three-fold benefit/harm ratio (NND) in Finland compared with Sweden may indicate 
that it is more strongly affected by mortality reduction (NNI) than excess incidence (NNO), 
as NNI showed a larger (seven-fold difference) between the two countries. Likewise, 
substantial differences emerged between the volunteer-based efficacy trials, with both 
mortality impact (NNI) and excess incidence (NNO) at least twice as high for Belgium than 
the Netherlands. This could be attributable to the very long screening interval in Belgium 
(seven years). 
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Finding an optimal balance is probably not possible simply by maximizing only detection or 
minimizing overdiagnosis, but it requires consideration of several aspects of the screening 
program. The findings indicate that an aggressive screening protocol with a large 
proportion of screen-positive results is likely to increase both harms and benefits. 
However, the favorable overall balance of effects shown for Sweden (with an NND of 12) 
seem to depend mainly on the large absolute mortality reduction. One explanation could 
be that only an intensive or continuous screening can detect potentially lethal cancers at a 
curable stage. This likely leads also to increased diagnosis of indolent cases, while a less 
intense program yields fewer such cases, but also a small mortality reduction.   
The largest mortality reduction (smallest NNI) was seen in Sweden and the Netherlands. 
As they had the largest number of screening rounds, as well as the longest duration of 
screening (up to 20 years), this finding suggests that three screening rounds employed in 
the other centers may not be sufficient to provide a similar mortality benefit. The lack of a 
mortality reduction in Switzerland may reflect shorter follow-up, as the screening effect 
emerges only after 7-9 years of follow-up (18), but may also be chance fluctuation (the 
difference being due to only two additional deaths). The absolute mortality impact is likely 
to increase with additional follow-up, owing to the slow progression of the disease and 
substantial proportion of deaths occurring only 10-15 years or more after diagnosis. The 
extent of overdetection may on the hand decrease, as catch-up in the control arm is likely 
to continue for the duration of the lead-time gained in the screening arm (after cessation of 
screening). 
The results do not necessarily indicate which screening protocol is superior, because the 
harms and benefits are not commensurate. Most would agree that an averted prostate 
cancer death carries a higher impact than an overdiagnosed case. However, assessment 
of their relative weight is not straight forward, as it reflects value judgment (and various 
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preferences would likely yield contrasting evaluations of the optimal balance). One 
approach to improving the comparability between the different end-points is use of quality-
adjusted or disability-adjusted life-years (QALYs and DALYs). We have previously 
modelled the long-term impact of screening and performed a cost-effectiveness analysis 
using QALYs as indicator of the overall effects of screening (6,19).  
For reduction of overdiagnosis, multiparametric magnetic resonance imaging in guiding 
prostate biopsies has shown promise in detecting primarily clinically significant prostate 
cancer and reducing the yield of insignificant cancers (20). Novel, powerful prognostic 
markers would also allow identification of cases that would not require treatment and 
hence reduce overtreatment. Screening is likely to provide largest absolute benefit in the 
sub-groups with the highest risk, and correspondingly, the balance of benefit and harm is 
likely disadvantageous for low-risk men. Multifactorial risk stratification may allow 
identifying a target population with a superior screening effect. 
There are some caveats in the interpretation of the results. First, the number of 
observations is small, as each center as a unit of observation results in a material of only 
six or seven data points (depending on inclusion or exclusion of Switzerland and Spain). 
Second, all excess incidence does not necessarily constitute overdiagnosis, but may also 
reflect lead-time (earlier diagnosis due to screening) with subsequent catch-up by the 
control arm, as both absolute and relative excess incidence have decreased with the 
duration of follow-up (1). Further, a high prostate cancer incidence in the control arm may 
reflect contamination (opportunistic screening), and the low excess incidence in such 
context may be regarded as spurious. This is also one possible explanation for the small 
mortality benefit and modest excess incidence in Finland. In addition, cause of death 
attribution is prone to errors, which may affect the outcomes (13,21). Overall mortality is 
less prone to bias, but prostate cancer is an uncommon cause of death, which precludes a 
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reduction in overall mortality and limits the gain in life-years, as for most other screening 
programs (22,23). This does not, however, preclude any impact on life-years, as modelling 
studies have shown up to 100 life-years saved per 1000 screened men (19). 
In conclusion, the results indicate a strong interrelation between benefits and harms of 
prostate cancer screening. Decision-making about prostate cancer screening needs to 
involve judgment of the importance of averted prostate cancer death relative to 
unnecessary diagnosis and harms of treatment, to gauge the trade-offs between benefits 
and harms. With intensive screening, mortality reduction achievable may be larger, but the 
optimal balance between benefits and harms remain to be established. 
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